Methocarbamol

Relieves discomfort associated with acute, painful musculoskeletal conditions. Sold as Robaxin, Robaxin-750, Atmeksi. Every FDA application for this active ingredient: 3 branded and 72 generic.

As of Nov 14, 2026, FDA lists 75 applications for Methocarbamol (sold as Robaxin, Robaxin-750, Atmeksi), first approved Jul 16, 1957, with 0 new uses approved and 0 published complete response letters.

First approved: Jul 16, 1957
Applications: 75
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $65.3M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name


Methocarbamol	Part D	$64.5M	+79%	1,662,858
Tanlor	Part D	$826K	+886%	251
Methocarbamol	Part B	$6K	-8%	583

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

METHOCARBAMOL 1,000 MG TABLET: $8.35 per unitGeneric · new this year
METHOCARBAMOL 500 MG TABLET: $0.039 per unitGeneric · +6% in a year
METHOCARBAMOL 750 MG TABLET: $0.044 per unitGeneric · +1% in a year

Clinical Trials

12 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all


Suzetrigine for Analgesiain Arthroscopic Rotator Cuff RepairArtroscopic Surgery, Pain Management · University of Alabama at Birmingham	Phase 4	Not yet recruiting	Oct 8, 2026
Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated- Acute Kidney InjuryAcute Kidney Injury · River 2 Renal Corp.	Phase 2	Recruiting	Jun 4, 2026
Plasma Relaxin Measurement Based on Endometrial Preparation for Embryo TransferInfertility, Embryos Transfert · Hospices Civils de Lyon	—	Not yet recruiting	Mar 17, 2026
Examining Analgesic Synergy and Efficacy in Trauma CareOpioid Use Disorder · Wake Forest University Health Sciences	Phase 4	Not yet recruiting	Feb 27, 2026
Relaxin Therapy for Atrial FibrillationAtrial Fibrillation (AF), Arrhythmia · Deeptankar DeMazumder	Phase 1 / Phase 2	Not yet recruiting	Jan 22, 2026
An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain ServicePostsurgical Pain Management, Postsurgical Pain, Chronic · University of California, San Francisco	Phase 3	Not yet recruiting	Dec 22, 2025
Progressive Relaxation for COPD: Effects on Insomnia and SatisfactionCOPD, Insomnia · Ceylan Aksoy	Not applicable	Active, not recruiting	Apr 18, 2025
Reduce Opiate Exposure With ACL SurgeryAnterior Cruciate Ligament Injuries · Campbell Clinic	Phase 3	Enrolling by invitation	Aug 19, 2024

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history


Jul 16, 1957	Robaxin, Robaxin-750NDA 11011 · New molecular entity	Endo Operations	42	Discontinued
Jun 10, 1959	RobaxinNDA 11790 · New dosage form	Hikma	23	Marketed
Oct 22, 1974	MethocarbamolANDA 84231	Puracap Pharm	1	Discontinued
Feb 25, 1975	MethocarbamolANDA 84471	Puracap Pharm	4	Discontinued
May 16, 1975	MethocarbamolANDA 84486	Sun Pharm Industries	14	Discontinued
Jul 11, 1975	MethocarbamolANDA 84488	Sun Pharm Industries	13	Discontinued
Dec 19, 1975	MethocarbamolANDA 84615	Aiping Pharm Inc	32	Discontinued
Dec 19, 1975	MethocarbamolANDA 84616	Aiping Pharm Inc	33	Discontinued
Aug 11, 1976	MethocarbamolANDA 85159	Hikma Intl Pharms	26	Discontinued
Aug 18, 1976	MethocarbamolANDA 85123	Hikma	27	Discontinued
Aug 20, 1976	MethocarbamolANDA 84927	Impax Labs	10	Discontinued
Aug 20, 1976	MethocarbamolANDA 84928	Impax Labs	9	Discontinued
Aug 20, 1976	MethocarbamolANDA 85192	Watson Labs	18	Discontinued
Aug 25, 1976	MethocarbamolANDA 84448	Solvay	0	Discontinued
Aug 25, 1976	MethocarbamolANDA 84449	Solvay	0	Discontinued
Aug 26, 1976	MethocarbamolANDA 85180	Watson Labs	18	Discontinued
Nov 23, 1976	MethocarbamolANDA 84756	Chartwell Molecular	6	Discontinued
Jan 4, 1977	MethocarbamolANDA 84276	Ani Pharms	24	Discontinued
Mar 11, 1977	MethocarbamolANDA 84648	Ivax Sub Teva Pharms	0	Discontinued
Mar 11, 1977	MethocarbamolANDA 84649	Ivax Sub Teva Pharms	0	Discontinued
Mar 14, 1977	MethocarbamolANDA 84277	Ani Pharms	23	Discontinued
Aug 3, 1977	DelaxinANDA 85454	Ferndale Labs	0	Discontinued
Dec 19, 1977	MethocarbamolANDA 85963	Clonmel Hlthcare	11	Discontinued
Dec 19, 1977	MethocarbamolANDA 85961	Clonmel Hlthcare	14	Discontinued
Oct 29, 1979	MethocarbamolANDA 86988	Prinston Inc	7	Marketed
Feb 19, 1980	MethocarbamolANDA 85658	Kv Pharm	0	Discontinued
Feb 20, 1980	MethocarbamolANDA 85660	Kv Pharm	0	Discontinued
Jul 3, 1980	MethocarbamolANDA 86459	Dr Reddys	11	Discontinued
Dec 27, 1991	MethocarbamolANDA 89849	Marsam Pharms LLC	0	Discontinued
Sep 16, 1994	MethocarbamolANDA 87282	Sandoz	4	Discontinued
Sep 16, 1994	MethocarbamolANDA 87283	Sandoz	4	Discontinued
Jan 29, 2003	MethocarbamolANDA 40489	Oxford Pharms	2	Marketed
Mar 17, 2003	MethocarbamolANDA 40413	Able	0	Discontinued
Nov 6, 2009	MethocarbamolANDA 90200	Hetero Labs Ltd Iii	0	Marketed
Oct 21, 2011	MethocarbamolANDA 200958	Bostal	2	Marketed
Dec 5, 2014	MethocarbamolANDA 204404	Pharmobedient	0	Discontinued
May 27, 2016	MethocarbamolANDA 206128	Eugia Pharma	0	Marketed
Oct 27, 2016	MethocarbamolANDA 205354	Monterey Pharms LLC	0	Marketed
Jan 19, 2017	MethocarbamolANDA 208116	Hainan Poly	0	Marketed
Feb 8, 2017	MethocarbamolANDA 203550	Pharmobedient	3	Marketed
Jun 22, 2017	MethocarbamolANDA 207496	Am Regent	0	Marketed
Jul 18, 2017	MethocarbamolANDA 205404	Sagent Pharms Inc	0	Marketed
Jul 21, 2017	MethocarbamolANDA 208507	Regcon Holdings	0	Marketed
Jul 31, 2017	MethocarbamolANDA 207522	Somerset Theraps LLC	2	Marketed
Nov 24, 2017	MethocarbamolANDA 206071	Navinta LLC	0	Discontinued
Apr 17, 2018	MethocarbamolANDA 209331	Fresenius Kabi USA	0	Marketed
May 7, 2018	MethocarbamolANDA 209312	Granules	2	Marketed
Oct 26, 2018	MethocarbamolANDA 211504	Gland	1	Marketed
Aug 12, 2020	MethocarbamolANDA 213967	Aurobindo Pharma Ltd	1	Marketed
Apr 30, 2021	MethocarbamolANDA 212623	Pharmazone	0	Marketed
Jul 14, 2022	MethocarbamolANDA 215065	Baxter Hlthcare Corp	0	Discontinued
Jun 12, 2023	MethocarbamolANDA 212707	Pharmobedient	0	Marketed
Jul 30, 2025	AtmeksiNDA 219843	Rosemont Pharms	0	Marketed
—	MethocarbamolANDA 89418	Am Therap	0	Discontinued
—	MethocarbamolANDA 83605	Watson Labs	0	Discontinued
—	MethocarbamolANDA 84259	Mylan	0	Discontinued
—	MethocarbamolANDA 84323	Mylan	1	Discontinued
—	MethocarbamolANDA 84675	Heather	0	Discontinued
—	MethocarbamolANDA 84846	Tablicaps	0	Discontinued
—	MethocarbamolANDA 84924	Heather	0	Discontinued
—	MethocarbamolANDA 85033	Nylos	0	Discontinued
—	ForbaxinANDA 85136	Forest Labs	0	Discontinued
—	MethocarbamolANDA 85137	Inwood Labs	0	Discontinued
—	MethocarbamolANDA 85718	Purepac Pharm	0	Discontinued
—	MethocarbamolANDA 87453	Upsher Smith	0	Discontinued
—	MethocarbamolANDA 87454	Upsher Smith	0	Discontinued
—	MethocarbamolANDA 87589	Superpharm	0	Discontinued
—	MethocarbamolANDA 87590	Superpharm	0	Discontinued
—	MethocarbamolANDA 87660	Ascot	1	Discontinued
—	MethocarbamolANDA 87661	Ascot	1	Discontinued
—	MethocarbamolANDA 88646	Roxane	0	Discontinued
—	MethocarbamolANDA 88647	Roxane	0	Discontinued
—	MethocarbamolANDA 88731	Pioneer Pharms	0	Discontinued
—	MethocarbamolANDA 89082	Pioneer Pharms	0	Discontinued
—	MethocarbamolANDA 89417	Am Therap	0	Discontinued

Show all 75

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA